이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

2026년 5월 11일 업데이트: Sinovac Life Sciences Co., Ltd.

A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants

A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).

The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.

연구 개요

상태

아직 모집하지 않음

상세 설명

A phase III clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Philippines infants aged approximately 2 months (42 to 89 days).

The trial is a randomized, double-blind, active controlled study. The objective of this study is to evaluate the immunogenicity and safety of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Prevenar 13™ manufactured by Pfizer.

About 500 infants aged approximately 2 months (42 to 89 days) will be enrolled. Participants will be randomized in 1:1 ratio to the test group and control group.

연구 유형

중재적

등록 (추정된)

500

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Cavite
      • Imus, Cavite, 필리핀 제도
        • Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  1. Health infants aged approximately 2 months (42 to 89 days)
  2. Have a parent/legal guardian who has provided written informed consent after being fully informed about the study.
  3. Be able to provide the vaccination records since birth.
  4. The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).

Exclusion Criteria:

  1. Previous vaccination of any licensed or investigational pneumococcal vaccine, or planned receipt during the study participation;
  2. Previous vaccination of vaccines containing the component of diphtheria, tetanus, pertussis, poliomyelitis, and/or Hib vaccine.
  3. Previous receipt of ≥2 doses of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old.
  4. History of severe adverse reaction to previous vaccinations and/or serious allergic reactions (eg, anaphylaxis) to any vaccine component.
  5. History of any laboratory confirmed pneumococcal bacterial pneumonia or invasive pneumococcal diseases caused by S pneumoniae.
  6. Premature infants (born before week 37 of gestation).
  7. Severe congenital malformations, developmental disorders, clinically significant genetic defects, malnutrition.
  8. Autoimmune diseases or immunodeficiency/immunosuppression.
  9. Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.
  10. Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).
  11. Received immunosuppressive for ≥14 days (e.g., prednisone equivalent of ≥2 mg/kg), or cytotoxic drug before enrollment, or plans to receive these treatments during the study participation.
  12. Received blood products before investigational vaccine inoculation, or plan to receive these treatments during study participation.
  13. Received other investigational drugs/vaccines before enrollment, or plan to receive investigational drugs/vaccines during study participation.
  14. Received live attenuated vaccines or nucleic-acid vaccines within 14 days before enrollment.
  15. Received subunit or inactivated vaccines within 7 days before enrollment.
  16. Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.
  17. Axillary temperature ≥ 37.5°C before enrollment.
  18. Any other factors judged by the investigators as unsuitable for participation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Sinovac PCV 13
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
활성 비교기: Prevenar 13™
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
기간: 30 days after dose 2.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 2.
30 days after dose 2.
Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.
기간: 30 days after dose 2
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 2.
30 days after dose 2

2차 결과 측정

결과 측정
측정값 설명
기간
이상반응 발생률
기간: 각 투여 후 0~7일
각 투여 후 7일 이내에 이상반응 발생률
각 투여 후 0~7일
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
기간: 30 days after dose 3.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 3.
30 days after dose 3.
Geometric mean concentrations (GMCs ) of serotype-specific IgG antibody.
기간: 30 days after dose 3.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 3.
30 days after dose 3.
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL
기간: 30 days after dose 2
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 2
30 days after dose 2
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL .
기간: 30 days after dose 3
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 3.
30 days after dose 3
GMC fold increases (GMFRs) in IgG antibody concentrations.
기간: From before dose 3 to 30 days after dose 3
GMC fold increases (GMFRs) in IgG antibody concentrations from before dose 3 to 30 days after dose 3.
From before dose 3 to 30 days after dose 3
Percentage of participants with serotype-specific opsonophagocytosis assay (OPA) antibody titers ≥1:8
기간: 30 days after the dose 2.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 2.
30 days after the dose 2.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8.
기간: 30 days after the dose 3.
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 3.
30 days after the dose 3.
Geometric mean titers (GMTs) of serotype-specific OPA antibody.
기간: 30 days after dose 2.
Geometric mean titers (GMTs) of serotype-specific OPA antibody 30 days after dose 2.
30 days after dose 2.
GMTs of serotype-specific OPA antibody .
기간: 30 days after dose 3.
GMTs of serotype-specific OPA antibody at 30 days after dose 3.
30 days after dose 3.
GMT fold rises (GMFRs) in OPA titers.
기간: From before dose 3 to 30 days after dose 3.
GMT fold rises (GMFRs) in OPA titers from before dose 3 to 30 days after dose 3.
From before dose 3 to 30 days after dose 3.
Incidence of adverse reactions
기간: 0-30 days after each dose.
Incidence of adverse reactions within 30 days after each dose.
0-30 days after each dose.
Incidence of serious adverse events(SAEs)
기간: From dose 1 to 30 days after dose 3
Incidence of SAEs from dose 1 to 30 days after dose 3
From dose 1 to 30 days after dose 3
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL
기간: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL
기간: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration
기간: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration ≥ the observed anti-pertussis antibody concentration achieved by 95% of Prevenar 13™ recipients at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL
기간: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL
기간: 30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL at 30 days after dose 3 of DTwP-HepB-Hib
30 days after dose 3 of DTwP-HepB-Hib
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8
기간: 30 days after dose 3 of IPV
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8 measured at 30 days after dose 3 of IPV
30 days after dose 3 of IPV

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Edison Alberto, Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 5월 1일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2027년 7월 1일

연구 등록 날짜

최초 제출

2026년 5월 11일

QC 기준을 충족하는 최초 제출

2026년 5월 11일

처음 게시됨 (실제)

2026년 5월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 11일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • PRO-PCV13-3003

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다